Irish Iterum files for IPO on NasdaqIterum Therapeutics plans to raise up to US$92m in an initial public offering on US technology stock market Nasdaq. The Irish company develops oral and IV antibiotics for urinary tract infections and … more ➔
Near-term capital for NeurimmuneUS biotech company Biogen has exercised the option of a one-off payment to Swiss developer Neurimmune. If Biogen’s Alzheimer’s candidate Aducanumab is approved, the sales-related payments to Neurimmune … more ➔
Diabetes drug reverses PAHA new study shows that a drug approved for the treatment of diabetes reverses pulmonary arterial hypertension (PAH) and prevents right heart failure in rats. Ekaterina Legchenko and colleagues say their … more ➔
Targovax gives pipeline updateNorwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou. more ➔
AZs Durvalumab/Tremelimumab combo flops...British drug maker AstraZeneca has failed to expand the reach of its combo of PD-1/CTLA4 checkpoint blockers Durvalumab/Tremelimumab. The approved second-line NSCLC treatment missed to prolong … more ➔
Palbociclib companion biomarker unraveledResearchers at the Universities of Dundee and Newcastle have identified a previously unknown target for the breast cancer drug palbociclib, which can be used to identify treatment responders. more ➔
GBS 2018: Bioeconomy leaders foster shift...International collaboration is needed to secure living of the growing world population without collapse of the planet’s resources, biodiversity and climate. A communique published at the end of the Global … more ➔
A bioengineered tattoo monitors blood calc...Swiss researchers have created a biomedical tattoo that becomes visible on the skin of mice in response to elevated levels of calcium in the blood. more ➔
German biotech sector growingThe German biotech industry has shown tremendous growth in 2017. According to figures of BIOCOM, turnover, employees or number of start-ups – many key figures for 2017 exceeded those of the record year … more ➔
Servier to bag Shire’s cancer busine...French Servier boosts its cancer drug portfolio acquiring Shire plcs oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash. more ➔
